Study drug for hard-to-treat advanced solid cancers or lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests TSN222 in people with advanced, hard-to-treat solid tumors or lymphomas. It aims to see whether the drug can shrink tumors or improve outcomes, including in specific cancer types like head and neck cancer and melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and agree to join the study in writing
- Your overall health is good enough for treatment (ECOG performance status 0 or 1)
- You have advanced, unresectable cancer that’s either not responding to standard treatment or no standard option exists
- You can provide a tumor sample (biopsy) and are willing to give tissue during the study
- There is at least one measurable tumor spot (for the Phase 2 part), and it cannot be injected or biopsied during the study
- Your body functions are adequate (bone marrow, kidneys, liver) based on blood tests and you have enough heart/lung health
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This trial tests an experimental drug called TSN084 for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.